Claudia Bellofiore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Claudia Bellofiore has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Giovanni Palladini
University of Pavia and Foundation IRCCS Policlinico San Matteo, Pavia, Italy
12 shared publications - Marco Basset
Department of Molecular Medicine, University of Pavia, Pavia, Italy
9 shared publications - Paolo Milani
Department of Molecular Medicine, University of Pavia, Pavia, Italy
9 shared publications - Giampaolo Merlini
Amyloid Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, and University of Pavia
8 shared publications - Mario Nuvolone
Department of Molecular Medicine, University of Pavia, Pavia, Italy
7 shared publications - Andrea Foli6 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Wiley in American Journal of Hematology
Outcomes of Patients With AL Amyloidosis and End‐Stage Renal Disease After Initiation of Therapy
In AL amyloidosis, advanced renal disease can impact treatment options and cause significant morbidity. Patients with ESRD requiring dialysis are a group with currently unmet needs. In this collaborative study, we identified 362 patients from three European centers who initiated dialysis during the course of the disease. Median survival after the initiation of dialysis was 40 months. Heart involvement, higher BMPC infiltration at diagnosis, and lambda light chain type were associated with inferior survival. At the time of dialysis initiation, cardiac biomarkers were prognostic for postdialysis outcome, but they did not perform the same as in patients not on dialysis. Higher FLCs levels at dialysis initiation were also prognostic, independently of cardiac biomarkers and other adverse factors. After starting dialysis, 151 patients received further treatment; median postdialysis survival for those that achieved CR/VGPR was significantly improved with 63.8 vs. 42 months for patients who achieved PR or less. In conclusion, patients with AL amyloidosis that require dialysis still represent a group of patients with poor outcomes, although, they can have prolonged postdialysis survival if they achieve deep hematologic response and have limited cardiac and clonal disease; such patients could also be considered for renal transplantation.
- 21 October 2026
- Published by Wiley in American Journal of Hematology
Open AccessOutcomes of Patients With AL Amyloidosis and End‐Stage Renal Disease After Initiation of Therapy
In AL amyloidosis, advanced renal disease can impact treatment options and cause significant morbidity. Patients with ESRD requiring dialysis are a group with currently unmet needs. In this collaborative study, we identified 362 patients from three European centers who initiated dialysis during the course of the disease. Median survival after the initiation of dialysis was 40 months. Heart involvement, higher BMPC infiltration at diagnosis, and lambda light chain type were associated with inferior survival. At the time of dialysis initiation, cardiac biomarkers were prognostic for postdialysis outcome, but they did not perform the same as in patients not on dialysis. Higher FLCs levels at dialysis initiation were also prognostic, independently of cardiac biomarkers and other adverse factors. After starting dialysis, 151 patients received further treatment; median postdialysis survival for those that achieved CR/VGPR was significantly improved with 63.8 vs. 42 months for patients who achieved PR or less. In conclusion, patients with AL amyloidosis that require dialysis still represent a group of patients with poor outcomes, although, they can have prolonged postdialysis survival if they achieve deep hematologic response and have limited cardiac and clonal disease; such patients could also be considered for renal transplantation.
- Open Access
Long-Term Survival with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients—A Survey from Two Italian Centers
Background: Multiple myeloma (MM) is a clonal plasma cell neoplasm representing the second most common hematological malignancy. The combination of daratumumab, lenalidomide and dexamethasone (D-Rd) was first approved by the EMA (European Medicines Agency) for the treatment of relapsed/refractory multiple myeloma (RRMM) patients, and was subsequently approved for first-line therapy, based on the results of POLLUX and MAIA trials, respectively. Methods: In this survey, we retrospectively collected data from 96 consecutive transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) patients treated with the D-Rd combination. Results: The median age was 73 years; the median progression free survival (mPFS) and median overall survival (mOS) were not reached (NR); the overall response rate (ORR), defined as patients who obtained at least a partial response (PR), was 90%; 59% of patients achieved a very good partial response (VGPR) or better. A strong negative correlation was observed between treatment response and elevated beta-2-microglobulin levels. Conclusions: This study confirms the efficacy of the D-Rd combination as first-line therapy for TIE-NDMM patients, suggesting that achieving at least a PR—and particularly a VGPR—may represent a strong predictor of long-term remission and survival, even in the era of new combinations based on the use of quadruplets.
Open AccessLong-Term Survival with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients—A Survey from Two Italian Centers
Background: Multiple myeloma (MM) is a clonal plasma cell neoplasm representing the second most common hematological malignancy. The combination of daratumumab, lenalidomide and dexamethasone (D-Rd) was first approved by the EMA (European Medicines Agency) for the treatment of relapsed/refractory multiple myeloma (RRMM) patients, and was subsequently approved for first-line therapy, based on the results of POLLUX and MAIA trials, respectively. Methods: In this survey, we retrospectively collected data from 96 consecutive transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) patients treated with the D-Rd combination. Results: The median age was 73 years; the median progression free survival (mPFS) and median overall survival (mOS) were not reached (NR); the overall response rate (ORR), defined as patients who obtained at least a partial response (PR), was 90%; 59% of patients achieved a very good partial response (VGPR) or better. A strong negative correlation was observed between treatment response and elevated beta-2-microglobulin levels. Conclusions: This study confirms the efficacy of the D-Rd combination as first-line therapy for TIE-NDMM patients, suggesting that achieving at least a PR—and particularly a VGPR—may represent a strong predictor of long-term remission and survival, even in the era of new combinations based on the use of quadruplets.
- Open Access
- 16 February 2026
- Published by Wiley in HemaSphere
- Vol. 10 (2)
Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real‐world patients
- 16 February 2026
- Published by Wiley in HemaSphere
- Vol. 10 (2)
Open AccessEligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real‐world patients
- Open Access
- 29 April 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (9) , 2221-2225
Diffuse lung involvement as a rare presentation of systemic AL amyloidosis: a retrospective cohort study
- 29 April 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (9) , 2221-2225
Open AccessDiffuse lung involvement as a rare presentation of systemic AL amyloidosis: a retrospective cohort study
- Open Access
- 24 March 2025
- Published by Wiley in HemaSphere
- Vol. 9 (3) , e70112
Daratumumab‐based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case‐control study
- 24 March 2025
- Published by Wiley in HemaSphere
- Vol. 9 (3) , e70112
Open AccessDaratumumab‐based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case‐control study
- 2 June 2024
- Published by Wiley in Hematological Oncology
- Vol. 42 (4) , e3289
A real‐life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis
Daratumumab‐based regimens are the new standard of care for newly diagnosed patients with AL amyloidosis based on the results of the ANDROMEDA study. However, real‐world data on daratumumab efficacy in upfront therapy in unselected patients are scanty. In the framework of a prospective observational study, we investigated the efficacy and safety of daratumumab in 88 newly diagnosed patients, including subjects with IIIb cardiac stage (26%) or myeloma defining events (29%). Daratumumab was administered with bortezomib in 50 (56%) patients, lenalidomide in 31 (35%), and monotherapy in 7 (8%). The rate of serious adverse events was low (16%). The overall hematologic response rate was 75% with 52 (59%) patients attaining at least a very good partial response (VGPR) at six months. Amongst patients evaluable for organ response, the rate of cardiac and renal responses at 6 months was 31% and 21%, respectively. Comparing stage IIIb patients with the remaining ones, the rate of profound hematologic response was not significantly different (≥VGPR 57% vs. 59%, p 0.955) likewise the rate of cardiac (33% vs. 30%, p 0.340) and renal (40% vs. 16%, p 0.908) responses. Daratumumab‐based regimens demonstrated to be safe and effective in treatment‐naïve AL amyloidosis even in advanced stage disease.
- 2 June 2024
- Published by Wiley in Hematological Oncology
- Vol. 42 (4) , e3289
A real‐life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis
Daratumumab‐based regimens are the new standard of care for newly diagnosed patients with AL amyloidosis based on the results of the ANDROMEDA study. However, real‐world data on daratumumab efficacy in upfront therapy in unselected patients are scanty. In the framework of a prospective observational study, we investigated the efficacy and safety of daratumumab in 88 newly diagnosed patients, including subjects with IIIb cardiac stage (26%) or myeloma defining events (29%). Daratumumab was administered with bortezomib in 50 (56%) patients, lenalidomide in 31 (35%), and monotherapy in 7 (8%). The rate of serious adverse events was low (16%). The overall hematologic response rate was 75% with 52 (59%) patients attaining at least a very good partial response (VGPR) at six months. Amongst patients evaluable for organ response, the rate of cardiac and renal responses at 6 months was 31% and 21%, respectively. Comparing stage IIIb patients with the remaining ones, the rate of profound hematologic response was not significantly different (≥VGPR 57% vs. 59%, p 0.955) likewise the rate of cardiac (33% vs. 30%, p 0.340) and renal (40% vs. 16%, p 0.908) responses. Daratumumab‐based regimens demonstrated to be safe and effective in treatment‐naïve AL amyloidosis even in advanced stage disease.
- 10 May 2024
- Published by Morressier GmbH
A phase II study of daratumumab and pomalidomide in previously treated patients with AL amyloidosis OA10 (#466)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 10 May 2024
- Published by Morressier GmbH
A phase II study of daratumumab and pomalidomide in previously treated patients with AL amyloidosis OA10 (#466)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 10 May 2024
- Published by Morressier GmbH
New reference ranges of free light chain ratio: impact on clinical practice in AL and ATTRwt amyloidosis PB83 (#443)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 10 May 2024
- Published by Morressier GmbH
New reference ranges of free light chain ratio: impact on clinical practice in AL and ATTRwt amyloidosis PB83 (#443)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 10 May 2024
- Published by Morressier GmbH
Bone marrow-free sequencing of M protein genes: a liquid biopsy approach in monoclonal gammopathies OA5 (#464)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 10 May 2024
- Published by Morressier GmbH
Bone marrow-free sequencing of M protein genes: a liquid biopsy approach in monoclonal gammopathies OA5 (#464)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 10 May 2024
- Published by Morressier GmbH
Outcomes of patients with AL amyloidosis and end-stage renal disease after initiation of therapy OA16 (#501)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 10 May 2024
- Published by Morressier GmbH
Outcomes of patients with AL amyloidosis and end-stage renal disease after initiation of therapy OA16 (#501)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER